Organogenesis Holdings Inc.

Informe acción NasdaqCM:ORGO

Capitalización de mercado: US$326.1m

Organogenesis Holdings Dirección

Dirección controles de criterios 3/4

El CEO de Organogenesis Holdings' es Gary Gillheeney , nombrado en Jan 2014, tiene una permanencia de 10.42 años. compensación anual total es $6.24M, compuesta por 14.6% salario y 85.4% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.63% de las acciones de la empresa, por valor de $2.08M. La antigüedad media del equipo directivo y de la junta directiva es de 6.8 años y 3.6 años, respectivamente.

Información clave

Gary Gillheeney

Chief Executive Officer (CEO)

US$6.2m

Compensación total

Porcentaje del salario del CEO14.6%
Permanencia del CEO10.4yrs
Participación del CEO0.6%
Permanencia media de la dirección6.8yrs
Promedio de permanencia en la Junta Directiva3.6yrs

Actualizaciones recientes de la dirección

We Think Organogenesis Holdings Inc.'s (NASDAQ:ORGO) CEO Compensation Package Needs To Be Put Under A Microscope

Jun 15
We Think Organogenesis Holdings Inc.'s (NASDAQ:ORGO) CEO Compensation Package Needs To Be Put Under A Microscope

Recent updates

We Think Organogenesis Holdings Inc.'s (NASDAQ:ORGO) CEO Compensation Package Needs To Be Put Under A Microscope

Jun 15
We Think Organogenesis Holdings Inc.'s (NASDAQ:ORGO) CEO Compensation Package Needs To Be Put Under A Microscope

Organogenesis Holdings: Small-Cap Biotech With Inconsistent Earnings And A Powerful Catalyst

Jun 10

Investors Can Find Comfort In Organogenesis Holdings' (NASDAQ:ORGO) Earnings Quality

May 21
Investors Can Find Comfort In Organogenesis Holdings' (NASDAQ:ORGO) Earnings Quality

Shareholders Should Be Pleased With Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Price

May 01
Shareholders Should Be Pleased With Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Price

Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?

Apr 10
Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?

These 4 Measures Indicate That Organogenesis Holdings (NASDAQ:ORGO) Is Using Debt Reasonably Well

Jan 04
These 4 Measures Indicate That Organogenesis Holdings (NASDAQ:ORGO) Is Using Debt Reasonably Well

Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?

May 31
Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?

Does Organogenesis Holdings (NASDAQ:ORGO) Have A Healthy Balance Sheet?

Jan 19
Does Organogenesis Holdings (NASDAQ:ORGO) Have A Healthy Balance Sheet?

Organogenesis: Finding A Spot For This Regenerative Medicines Company In My 'Bio Boom' Portfolio

Oct 18

Here's Why Organogenesis Holdings (NASDAQ:ORGO) Can Manage Its Debt Responsibly

Sep 23
Here's Why Organogenesis Holdings (NASDAQ:ORGO) Can Manage Its Debt Responsibly

Organogenesis gets FDA clearance for PuraPly MZ for wound healing

Aug 15

Here's Why Organogenesis Holdings (NASDAQ:ORGO) Has Caught The Eye Of Investors

Jul 28
Here's Why Organogenesis Holdings (NASDAQ:ORGO) Has Caught The Eye Of Investors

Here's Why Organogenesis Holdings (NASDAQ:ORGO) Can Manage Its Debt Responsibly

Jun 10
Here's Why Organogenesis Holdings (NASDAQ:ORGO) Can Manage Its Debt Responsibly

Organogenesis Holdings: What Now

May 18

The Market Doesn't Like What It Sees From Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Earnings Yet

Mar 31
The Market Doesn't Like What It Sees From Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Earnings Yet

These 4 Measures Indicate That Organogenesis Holdings (NASDAQ:ORGO) Is Using Debt Reasonably Well

Mar 04
These 4 Measures Indicate That Organogenesis Holdings (NASDAQ:ORGO) Is Using Debt Reasonably Well

Organogenesis Holdings (NASDAQ:ORGO) Seems To Use Debt Quite Sensibly

Nov 30
Organogenesis Holdings (NASDAQ:ORGO) Seems To Use Debt Quite Sensibly

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Gary Gillheeney en comparación con los beneficios de Organogenesis Holdings?
FechaCompensación totalSalarioIngresos de la empresa
Mar 31 2024n/an/a

US$6m

Dec 31 2023US$6mUS$909k

US$5m

Sep 30 2023n/an/a

US$13m

Jun 30 2023n/an/a

US$10m

Mar 31 2023n/an/a

US$13m

Dec 31 2022US$6mUS$883k

US$16m

Sep 30 2022n/an/a

US$59m

Jun 30 2022n/an/a

US$71m

Mar 31 2022n/an/a

US$83m

Dec 31 2021US$4mUS$835k

US$94m

Sep 30 2021n/an/a

US$62m

Jun 30 2021n/an/a

US$69m

Mar 31 2021n/an/a

US$43m

Dec 31 2020US$3mUS$823k

US$17m

Sep 30 2020n/an/a

-US$5m

Jun 30 2020n/an/a

-US$37m

Mar 31 2020n/an/a

-US$42m

Dec 31 2019US$1mUS$819k

-US$39m

Sep 30 2019n/an/a

-US$46m

Jun 30 2019n/an/a

-US$48m

Mar 31 2019n/an/a

-US$58m

Dec 31 2018US$3mUS$798k

-US$65m

Sep 30 2018n/an/a

-US$60m

Jun 30 2018n/an/a

-US$52m

Mar 31 2018n/an/a

-US$32m

Dec 31 2017US$1mUS$780k

-US$9m

Compensación vs. Mercado: La compensación total de Gary($USD6.24M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD2.44M).

Compensación vs. Ingresos: La compensación de Gary ha sido consistente con los resultados de la empresa en el último año.


CEO

Gary Gillheeney (69 yo)

10.4yrs

Permanencia

US$6,244,671

Compensación

Mr. Gary S. Gillheeney, Sr. has been the Chief Executive Officer and President of Organogenesis Holdings Inc. since 2014 and has been its Director since December 10, 2018 & serves as its Chair of the Board...


Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Gary Gillheeney
President10.4yrsUS$6.24m0.63%
$ 2.1m
David Francisco
Chief Financial Officer3.3yrsUS$1.63m0.048%
$ 157.1k
Patrick Bilbo
Chief Operating Officer6.8yrsUS$2.16m0.26%
$ 853.8k
Lori Freedman
Chief Administrative & Legal Officer7.4yrsUS$1.99m0.063%
$ 206.4k
Brian Grow
Chief Commercial Officer6.8yrsUS$1.92m0.078%
$ 255.4k
William Kolb
Secretaryno datasin datossin datos
Robert Cavorsi
Vice President of Strategy3.4yrssin datossin datos

6.8yrs

Permanencia media

57.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de ORGO es experimentado (6.8 años antigüedad media).


Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Gary Gillheeney
President5.5yrsUS$6.24m0.63%
$ 2.1m
Glenn Nussdorf
Director21.4yrssin datos11.29%
$ 36.8m
Alan Ades
Director21.4yrssin datos11.5%
$ 37.5m
Arthur Leibowitz
Lead Independent Director5.5yrsUS$291.46k0.10%
$ 336.0k
Robert Ades
Director3.6yrssin datossin datos
Jon Giacomin
Independent Director3.1yrsUS$265.00k0.068%
$ 221.0k
Michele Korfin
Independent Director2.1yrsUS$226.98k0.068%
$ 220.5k
Prathyusha Duraibabu
Independent Director2.6yrsUS$240.00k0.071%
$ 230.9k
David Erani
Director3.6yrssin datossin datos
Michael Driscoll
Independent Director2.3yrsUS$230.52ksin datos
Gilberto Quintero
Independent Director2.1yrsUS$226.98k0.068%
$ 220.5k

3.6yrs

Permanencia media

59yo

Promedio de edad

Junta con experiencia: La junta directiva de ORGO se considera experimentada (3.6 años de antigüedad promedio).